Resources Repository
-
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Evidence Synthesis | Value of Information | Health/Medicine | Economics/Finance | North America | Preferences/Values | Priority Setting/Ethics | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Chronic Disease/Risk | Mental Health | Health Systems | Business/Industry | Government/Law | Science/Technology | Europe -
BookPublication 2015Methods for the Economic Evaluation of Health Care Programmes, 4th Edition
The 2015 edition of Methods for the Economic Evaluation of Health Care Programmes provides a …
The 2015 edition of Methods for the Economic Evaluation of Health Care Programmes provides a 'tool kit' for undertaking health economic evaluations. The report is aimed at researchers, health service professionals and policy makers without a formal economics background. The recommendations are based on the authors' own experiences and so are practical in nature. The book describes the challenges of allocating resources efficiently and fairly, including challenges in methodology and policy formation. Examples are provided.…
Evidence Synthesis | Value of Information | Health/Medicine | Economics/Finance | North America | Preferences/Values | Priority Setting/Ethics | Costing Methods | Health Outcomes | Mathematical Models | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Science/Technology | Global | Europe -
BookPublication 2013Medical Decision Making
This new edition of Medical Decision Making provides a review of the key decision making infrastructure …
This new edition of Medical Decision Making provides a review of the key decision making infrastructure of clinical practice and explains the principles of medical decision making both for individual patients and the wider health care arena. Targeted to clinicians interested in medical decision making, it demonstrates how to make the best clinical decisions based on the available evidence and how to use clinical guidelines and decision support systems in electronic medical records to shape practice…
State-Transition | Value of Information | Health/Medicine | Economics/Finance | North America | Probability/Bayes | Preferences/Values | Costing Methods | Health Outcomes | Test Performance | Decision Analysis | Cost-Effectiveness Analysis | Europe | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
BookPublication 1996Cost-Effectiveness in Health and Medicine, 1st Edition
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and …
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and scholars with expertise in economics, clinical medicine, ethics, and statistics to review the state of cost-effectiveness analysis and to develop recommendations for its conduct and use in health and medicine. Publishing their results in 1996, they proposed the most explicit set of guidelines (together with their rationale) ever defined on the conduct of CEAs. The panel recommended analysts include a "reference-case"…
Evidence Synthesis | Value of Information | Health/Medicine | Economics/Finance | North America | Preferences/Values | Priority Setting/Ethics | Costing Methods | Health Outcomes | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation -
BookPublication 1980Clinical Decision Analysis
This text was conceived and developed in the Harvard T.H. Chan School of Public Health …
This text was conceived and developed in the Harvard T.H. Chan School of Public Health at the Center for the Analysis of Health Practices. The book had its origins in a set of classroom materials developed during the academic year 1974-75 for an elective course in medical decision making at the Harvard Medical School. In this book students are shown how to structure clinical decision problems, how to systematically formulate the intertwining roles of diagnosis and treatment, how to…
State-Transition | Value of Information | Health/Medicine | Economics/Finance | North America | Probability/Bayes | Preferences/Values | Costing Methods | Health Outcomes | Test Performance | Decision Analysis | Cost-Effectiveness Analysis | Infectious Diseases | Child/Nutrition | Chronic Disease/Risk | Global | Europe | Graduate | Doctoral | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
ArticlePublication 2023Benefits and Costs of COVID-19 Vaccine Mandates
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations …
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations for U.S. federal employees and healthcare and private sector workers. These mandates were controversial and some were halted by litigation. If they had been implemented as intended, the net benefits would depend on the course of the pandemic. If a more transmissible variant (such as Omicron) emerges, the net benefits may be large. If the pandemic instead fades, the benefits…
State-Transition | Health/Medicine | Economics/Finance | North America | Mathematical Models | Benefit-Cost Analysis | Infectious Diseases | Policy/Regulation | Business/Industry | Government/Law -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
State-Transition | Value of Information | Economics/Finance | North America | Benefit-Cost Analysis | Infectious Diseases | Policy/Regulation | Europe -
ReviewPublication 2022Systematic Review of Economic Evaluations of COVID-19 Interventions: Non-Health Impacts and Distributional Issues
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether …
The authors conducted a systematic review of economic evaluations of COVID-19 interventions and assessed whether they incorporated non-health impacts and distributional concerns. Among the 70 articles included, more than half (56%) included at least one non-health impact, although only 21% incorporated non-economic consequences. Only 17% examined subgroups of interest. The median ICER for the entire sample was $67,000/quality-adjusted life-year (QALY) (interquartile range [IQR] $9000-$893,000/QALY). Interventions including a pharmaceutical component yielded a median ICER of $93,000/QALY (IQR…
Evidence Synthesis | Health/Medicine | Economics/Finance | North America | Cost-Effectiveness Analysis | Infectious Diseases | Social Determinants | Culture/Society -
ArticlePublication 2021COVID-19 Vaccine Hesitancy: The Five C's to Tackle Behavioral and Sociodemographic Factors
Reversing and mitigating the ongoing damage associated with the COVID-19 pandemic requires that 60-70% of …
Reversing and mitigating the ongoing damage associated with the COVID-19 pandemic requires that 60-70% of the world’s population needs to be vaccinated. This article acknowledges that hesitancy is one of the most substantial hurdles to vaccination uptake at levels that would achieve herd immunity. Authors define hesitancy as “a delay in acceptance or refusal despite availability.” Five factors are proposed to tackle vaccine hesitancy, referred to as the five “C’s”: Confidence (importance, safety and efficacy…
Evidence Synthesis | Decision Psychology | Health/Medicine | North America | Preferences/Values | Health Outcomes | Infectious Diseases | Social Determinants | Culture/Society | Science/Technology